Mark Stevenson has joined General Atlantic as a senior advisor after decades in the life sciences sector.
He is slated to provide strategic counsel and support to the $72 billion firm’s investment teams and portfolio companies. General Atlantic added life sciences as a core sector in 2020 and has invested more than $2.5 billion in over 25 portfolio companies in the sector globally.
“Mark has a strong track record leading public and private companies and driving strategic growth, leveraging his expertise across many areas within life sciences including genomics and enabling tools,” said Brett Zbar, MD, managing director and global head of life sciences at New York-based General Atlantic. “We believe he will bring great value to our portfolio and be an important partner to our Life Sciences team in seeking to identify emerging and compelling opportunities for investment in what we view as a golden age of biology.”
Stevenson had served as executive vice president and chief operating officer at Thermo Fisher Scientific, where he was responsible for the company’s portfolio of life science, analytical and diagnostic businesses as well as the company’s innovation and digital strategy. He remains on Thermo Fisher’s scientific advisory board. He was president of Life Sciences Solutions prior to Thermo Fisher’s acquisition of the company in 2014.
“I share General Atlantic’s conviction in the large and growing global opportunity set within life sciences,” said Stevenson. “I look forward to working with Brett and the General Atlantic team as we work to identify and support entrepreneurs seeking to scale the companies that are driving the next wave of biotechnology innovation.”
